Objective Diabetes mellitus is associated with high rates of restenosis and adverse outcomes after percutaneous transluminal coronary angioplasty (PTCA). It is unclear whether coronary stenting reduces adverse events in diabetic patients after PTCA. Our purpose was to determine whether coronary stenting improves clinical event rates in diabetic patients after PTCA.
Methods
The Routine Versus Selective Exercise Treadmill Testing After Angioplasty (ROSETTA) registry was a prospective multicenter observational study examining functional testing and adverse outcomes after successful PTCA.
Results:
Among the 791 patients enrolled, 180 were diabetic. A total of 90 diabetics received stents while the remaining 90 patients did not. Baseline clinical characteristics were similar between the 2 groups of patients. However, patients with stents were more likely to have complex lesions, whereas those without stents were more likely to undergo atherectomy and have greater residual coronary stenosis. At 6-month follow-up, the composite end point defined as cardiac death, unstable angina, myocardial infarction, need for repeat PTCA, or coronary artery bypass graft surgery (CABG) occurred in 25.0% of stented and 22.2% of nonstented diabetic patients (P not significant [NS] ). A multivariate logistic regression analysis showed that coronary stenting was not associated with a reduced incidence of the composite end point among diabetic patients (odds ratio 0.97, 95% CI 0.46-2.05, P NS). cularization were included as were patients undergoing PTCA in venous or arterial bypass grafts.
Conclusion
The exclusion criteria of the study were participation in conflicting clinical studies, contraindications to repeat cardiac procedures (cardiac catheterization, PTCA, coronary bypass surgery), contraindications, or inability to undergo follow-up functional testing, presence of a medical condition with a survival prognosis <1 year, and being likely to be unavailable for a 6-month follow-up.
Diabetes mellitus was defined as hyperglycemia treated with diet, oral hypoglycemics, or insulin. Diabetic patients were identified by review of medical records and by patient self-report. Three patients with unavailable data on their diabetic status were excluded from the final analysis.
Baseline clinical and procedural characteristics
At the time of enrollment, baseline and procedural information was collected. This information included demographic data as well as clinical characteristics such as comorbid conditions, prior procedures, functional testing, and medical therapy. Procedural characteristics included numbers and characteristics of the treated coronary lesions, types of devices used in the procedures, and pre-and post-PTCA stenosis severity.
Six-month follow-up
At 6 months after the PTCA, patients were contacted by telephone for information on clinical events and cardiac procedures during the follow-up period. Significant clinical outcomes included were death, cardiac death, myocardial infarction, unstable angina, repeat PTCA, and coronary artery bypass surgery (CABG). In addition to the telephone interview, the study coordinator also contacted the patient's cardiologist (and other physicians and institutions if necessary). Six-month data were available for 791 patients (95.8% of enrolled patients).
The diagnosis of myocardial infarction (MI) required at least 2 of the following: clinical symptoms, electrocardiographic evidence of Q wave, enzyme changes (more than double the normal upper limits of creatine kinase or significant elevation of creatine kinase-myocardial band). Unstable angina was defined as angina requiring repeat hospitalization after the initial PTCA. Repeat PTCA was defined as a repeat PTCA performed after being discharged from hospital for the index PTCA. The composite end point was defined as cardiac death, repeat MI, unstable angina, or repeat PTCA or CABG.
Data analysis
The final analysis was performed in 791 patients with 6-month data. Continuous data are presented as the mean ± SD. and dichotomous data are presented as percentages. Dichotomous predictors were examined with the Fisher exact test and continuous variables were examined with the Student t test. All statistical tests were 2 tailed, and a P value of ≤0.05 was considered to be statistically significant. If a particular baseline variable was associated with the composite end point by univariate analysis (with a P value ≤0.10), it was entered into a multivariate logistic regression model. Regression analysis was used to determine whether any clinical or procedural variable was independently associated with 6-month outcomes in diabetic patients.
Results

Baseline clinical characteristics
From the ROSETTA Registry, there were 180 diabetic patients identified, 90 of whom had intracoronary stenting. Table I shows the baseline clinical characteristics of the diabetic patients with and without coronary stenting. There were no significant differences in age and sex distribution, risk factors, and coronary anatomy. More than one fourth of these patients had a history of previous PTCA before the index PTCA. The majority of the patients of both groups had hyperlipidemia and hypertension, whereas only a minority of them were active smokers. A large proportion of patients had Canadian Cardiovascular Society (CCS) angina class III/IV. Table II demonstrates the procedural characteristics of the diabetic patients in the ROSETTA registry. The modalities of coronary percutaneous interventions were similar for both groups of patients except for greater use of atherectomy in the diabetic nonstented group. Percutaneous interventions on grafts were performed in only a minority of patients. The diabetic stented group had more multilesion PTCAs. The diabetic nonstented patients had more coronary lesions of American Heart Association (AHA)/American College of Cardiology (ACC) type A; however, the coronary stenoses were severe and similar in both groups of patients. The left anterior descending coronary artery was equally affected in both groups. The diabetic stented patients had less residual coronary stenoses (5% ± 11% vs 13.3% ± 13, P < .0001). Outcomes at 6-month follow-up Table III compares the 6-month outcomes among the stented and nonstented diabetic patients. Both groups of patients had high rates of major adverse clinical events at 6-month follow-up. Most of these adverse events were unstable angina. Only a minority of patients had cardiac deaths or MIs. More than 20% of the patients required repeat catheterization and 13% had repeat PTCA. CABG was necessary in only 2% of the diabetic patients. The composite end point occurred with similar frequency in these diabetic patients with and without coronary stenting (25.0% vs 22.2%, P = .73). Table IV reports the univariate analysis and multivariate analysis association of baseline clinical characteristics and the composite end point. The univariate analysis showed that Killip class III/IV, CCS class III/IV, angina before the index PTCA, and unstable angina as the main reason for PTCA were associated with the composite end point. However, only Killip class III/IV, CCS class III/IV, and angina before the index PTCA were independently associated with the composite end point by multivariate analysis. Even after being forced into the multivariate logistic regression model, successful coronary stent placement was not associated with the composite end point in diabetic patients after PTCA (odds ratio of 0.97, 95% CI 0.5-2.1).
Angiographic and procedural characteristics
Predictors of adverse outcomes in diabetic patients
Discussion
Our study was designed to examine the impact of coronary stenting on clinical outcomes in diabetic patients. Our results showed persistently high rates of adverse clinical and procedural outcomes in diabetic patients after PTCA, even with coronary stenting. Both univariate and multivariate analysis failed to show any benefit of coronary stenting in reducing the incidence of the composite end point in diabetic patients. Early trials of coronary stenting suggested that this technique decreased restenosis in diabetic patients after PTCA. 11, 12 However, recent studies reported higher rates of adverse outcomes and restenosis in diabetic patients than in nondiabetic patients after coronary stenting. [13] [14] [15] [16] Kastrati et al 13 showed that diabetes mellitus increased the risk of 6-month angiographic restenosis by 86%.
Several mechanisms may be responsible for the high rate of adverse outcomes in diabetic patients after percutaneous coronary intervention. Stent provides a rigid endovascular lattice preventing elastic recoil and vascular spasm at the angioplasty site of the coronary artery. 17, 18 Restenosis within a stent results from smooth muscle cell hyperplasia. 17, 18 Kornowski et al 19 demonstrated that diabetic patients have increased intimal hyperplasia after coronary stenting.
The increased intimal hyperplasia after vascular injuries, in diabetic patients, have been shown to be the result of the increased activities of platelet-derived, insulin-like fibroblast and transforming growth factors. [20] [21] [22] Diabetic patients also have impaired endothelial cells function with impaired activity of endothelium-derived relaxing factor [23] [24] [25] [26] and increased activity of endothelin-1. 27,28 Diabetic patients have increased platelet activation and aggregability. 29, 30 These hemostatic disturbances may promote in-stent thrombosis and contribute to the high rate of adverse clinical outcomes in diabetic patients. The benefit of abciximab in reducing the rate of adverse events after coronary stenting 31, 32 indirectly supports the importance of platelet activation in the pathogenesis of in-stent restenosis in diabetic patients.
In summary, diabetes mellitus alters many cellular and hemostatic responses to vascular injuries. 33, 34 All these factors may contribute to the exaggerated intimal hyperplasia of diabetic patients after percutaneous coronary intervention. This may explain why coronary stenting does not improve the event-free rate in these patients after PTCA.
Our study showed that CCS class III/IV was a strong predictor of the composite end point in diabetic patients (odds ratio 2.5, 95% CI 1.2-5.6, P = .02). Silva et al 35 demonstrated that diabetic patients with unstable angina have more plaque ulceration and coronary thrombi than do the nondiabetics. Coronary ulceration and thrombi may promote in-stent thrombosis and subsequently more adverse clinical outcomes in the diabetic patients with unstable angina before the index PTCA. Killip class III/IV was also a very strong predictor of the composite end point (odds ratio 6.7, 95% CI 1.3-35.8, P = .03). The composite end point also occurred more frequently in patients with angina before the index PTCA (odds ratio 3.5, 95% CI 1.2-10.3, P = .02). Prior angina is usually a marker of more extensive coronary disease and greater ischemic burden. The above high-risk features may predispose the treating physicians to reintervene in these patients.
Our results showed that CCS and Killip class III/IV and angina before the index PTCA were associated with the composite end point. The above clinical characteristics appeared to identify diabetic patients at higher risk for adverse outcomes after PTCA.
Limitations
Our study has several potential limitations. First, because the stented patients had more non-type A coronary lesions, their coronary stenosis was more likely to be more complex and more prone to restenosis. This is consistent with a selection bias by the interventionist to perform intracoronary stenting in these high-risk patients. Second, we lack data on many angiographic details such as length and exact location of the coronary stenosis, vessel caliber, and stent type and length. We did not collect data on whether the stented patients with multilesion PTCA had stents inserted at all the angioplasty sites. Third, our trial was completed before the use of abciximab became widely available. This medication reduces restenosis rates and improves clinical outcomes in diabetic stented patients. 31, 32 Finally, in view of the small sample size and total events, the statistical analysis can only be considered as exploratory. Our study was a secondary data analysis of a registry of patients undergoing PTCA. Because examining clinical outcomes in diabetic patients after coronary stenting was not a hypothesis defined a priori, our results should be confirmed prospectively.
Conclusion
In conclusion, our study did not show a benefit of coronary stenting in reducing adverse events of diabetic patients after PTCA. Large randomized prospective studies of coronary stenting focusing on diabetic patients, with the use of adjunctive glycoprotein IIb/IIIa inhibitors, are needed to clarify this issue.
